N4 Pharma upbeat on latest tumour suppression study data
(Sharecast News) - Specialist pharmaceutical developer N4 Pharma updated the market on its recent preclinical study with TNF alpha on Friday.
Read moreMon, 14th Sep 2020 09:04
(Sharecast News) - Specialist pharmaceutical developer N4 Pharma updated the market on its recent preclinical study with TNF alpha on Friday.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.
Read moreFriday 18 March | |
Caracal Gold PLC | AGM |
Chenavari Toro Income Fund Ltd | AGM |
Monday 21 March | |
Aferian PLC | AGM |
Altona Rare Earths PLC | AGM |
Helical PLC | GM re becoming REIT & buyback |
Inland Homes PLC | AGM |
Tuesday 22 March | |
Crest Nicholson Holdings PLC | AGM |
Hochschild Mining PLC | EGM re Amarillo Gold acquisition |
Hydro Hotel Eastbourne PLC | AGM |
Starvest PLC | AGM |
Sureserve Group plc | AGM |
Wynnstay Group PLC | AGM |
Wednesday 23 March | |
CML Microsystems PLC | GM re employee share plans |
Quartix Technologies PLC | AGM |
Strategic Equity Capital PLC | GM re: tender offer |
Thursday 24 March | |
BlackRock Throgmorton Trust PLC | AGM |
Independent Investment Trust PLC | AGM |
N4 Pharma PLC | AGM |
React Group PLC | AGM |
Copyright 2022 Alliance News Limited. All Rights Reserved. |
N4 Pharma PLC - Derbyshire, England-based pharmaceutical company - Reports a pretax loss of GBP1.8 million for 2021, widening 18% from GBP1.6 million the previous year. Says year focused on in vivo studies of Nuvec, a delivery system for cancer treatments and vaccines, which did not return any "meaningful" immunological response in studies carried out by Hamburg-based drug development company Evotec SE. Says that on the back of increased data the company can now narrow its focus on the oncology and gene therapy market.
Read moreTRADING UPDATES: Hiro plans acquisition vehicle IPO; Aquila reviews
Read moreTRADING UPDATES: Cordiant raises GBP200 million; Home REIT spends
Read more(Sharecast News) - Specialist treatment and vaccine delivery system developer N4 Pharma updated the market on its work plan on Tuesday, following "encouraging data" from its oncology research as announced on 13 December.
Read moreIN BRIEF: N4 Pharma to focus resources on gene therapy
Read more(Sharecast News) - Cancer treatment and vaccine delivery system developer N4 Pharma updated the market on data from its proof-of-concept programmes and ongoing activities on Monday.
Read moreIN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors
Read more(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced on Friday that it has been granted a patent for its 'Nuvec' cancer treatment and vaccine delivery system by the European Patent Office (EPO), specifically around its composition, particulate materials, and methods for making the particulate materials.
Read moreN4 Pharma secures patent in Europe for Nuvec, expects China to follow
Read moreTRADING UPDATES: Christie Group and Open Orphan swing to profit
Read moreTRADING UPDATES: Boku launches in Germany; Focusrite trading well
Read moreTRADING UPDATES: IG Design starts year well; Ilika in Stereax progress
Read more